NCT01030406View on ClinicalTrials.gov

Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Opioid Abuse
Interventions
DRUG

40/0mg taken first

8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses

DRUG

80/0mg taken first

8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses

DRUG

40/240mg taken first

8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses

DRUG

80/480mg taken first

8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses

DRUG

0/0mg taken first

Placebo All arms taken with a 48 hour washout between doses

Trial Locations (1)

84106

Lifetree Clinical Research, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Acura Pharmaceuticals Inc.

INDUSTRY

NCT01030406 - Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users | Biotech Hunter | Biotech Hunter